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Abstract
Objectives: This study explored the response of nasopharyngeal carcinoma cells to TGF-β1-induced growth 
suppression and investigated the roles of the TGF-β/Smad signaling pathway in nasopharyngeal carcinoma cells.
Methods: The cells of nasopharyngeal carcinoma cell line CNE2 were treated with TGF-β1. The growth responses of 
CNE2 cells were analyzed by MTT assay. The mRNA expression and protein subcellular localization of the TGF-β/Smad 
signaling components in the CNE2 were determined by real time RT-PCR and immunocytochemical analysis.
Results: We found that the growth of CNE2 cells was not suppressed by TGF-β1. The signaling proteins TβRII, Smad 7 
were expressed normally, while Smad2, Smad3, and Smad4 increased significantly at the mRNA level. TGF-β type II 
receptor and Smad7 had no change compared to the normal nasopharyngeal epithelial cells. In addition, Smad2 was 
phosphorylated to pSmad2, and the activated pSmad2 translocated into the nucleus from the cytoplasm, while the 
inhibitory Smad-Smad7 translocated from the nucleus to the cytoplasm after TGF-β1 stimulation.
Conclusion: The results suggested that CNE2 cells are not sensitive to growth suppression by TGF-β1, but the TGF-β/
Smad signaling transduction is functional. Further work is needed to address a more detailed spectrum of the TGF-β/
Smad signaling pathway in CNE2 cells.
Introduction
Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nancy arising from the mucosal epithelium of the
nasopharynx and has a high incidence of metastasis [1].
NPC is classified by the WHO into three histological
types: keratinizing squamous cell carcinoma (type I);
nonkeratinizing carcinoma, characterized as differenti-
ated (type II); or, undifferentiated (type III) [2]. Although
NPC is a rare malignancy in most parts of the world, it is
endemic in a few well-defined populations such as the
natives in southeast Asia [3], and the incidence of NPC
reported in southeast Asia is nearly 20-60 times higher
than that reported in the Western countries [4,5].
Development of NPCs are not well understood, the dis-
tinctive racial/ethnic and geographic distribution of NPC
worldwide suggest that both genetic traits and environ-
mental factors contribute to its development. Investiga-
tion of the molecular mechanisms could help illuminate
the causes and ultimately the prevention of this remark-
able disease. There have been scanty but emerging
reports on the importance of cytokines and growth fac-
tors in NPC, where most of these investigations have
attempted to understand the roles played by cytokines
and growth factors during development and chemopre-
vention in NPC. Of particular interest are the observa-
tions that NPC patients showed a lower level of
transforming growth factor-β1 (TGF-β1) in plasma, but a
high level in tumor tissues and surrounding stroma com-
pared to the healthy controls [6-9]. The TGF-β signaling
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Page 2 of 8pathway may play an important role in the carcinogenesis
of NPC.
TGF-β belongs to a superfamily of structurally- and
functionally-related cytokines, where the members of
this family regulate a wide spectrum of cellular responses,
including cell proliferation, differentiation, adhesion,
migration and apoptosis [10]. It is now known that TGF-β
is a cytokine that is a very potent inhibitor of cellular pro-
liferation in normal cells. Evidence indicates that loss of
the anti-proliferative responsiveness to TGF-β is a char-
acteristic of many tumor cells [11-13], suggesting poten-
tial roles of TGF-β and substantial components of the
TGF-β signal transduction pathway as tumor suppressors
[14]. The Smad proteins are the principal intracellular
components of the TGF-β signaling pathway, and it has
been demonstrated that Smad proteins represent the
most direct mediators for the transmission of signal from
the cell surface in the nucleus [15]. Studies have shown
that the expression of Smads is frequently altered in
human cancers, for example, Smad4 has been found fre-
quently inactivated in pancreatic [16,17], biliary[18], and
colorectal tumors [19]. Increased expression of Smad6
and Smad7 has also been described in human pancreatic
and prostate carcinomas [20,21], respectively.
The pathogenesis and the progression of numerous
cancers have been attributed to the disruption of normal
TGF-β signaling. However, the role of TGF-β signaling in
the carcinogenesis of NPC is largely unknown, and it is
not clear how NPC cells regulate TGF-β signaling in
response to growth. Understanding the molecular mech-
anism underlying the TGF-β/Smad signaling pathway
may provide a novel target for anticancer therapy. Herein,
we described an in vitro study to examine TGF-β1 activ-
ity and ability to suppress tumor cell growth in a human
NPC cell line. We conducted an analysis of the expression
patterns of the TGF-β/Smad signaling pathway, its recep-
tors and the intracellular Smads including Smad2, Smad3,
Smad4 and Smad7. We also investigated the protein
expression and subcellular localization of some compo-
nents of Smads in response to the stimulation of TGF-β1
in the NPC cell lines.
Materials and methods
Cell lines, cell culture and treatment
The nasopharyngeal carcinoma cell lines (CNE2) and the
immortalized nasopharyngeal epithelial cell line (NP69)
were provided by the Biopharmaceutical Research and
Development Center (Jinan University, Guangzhou,
China), and cultured in Keratinocyte-SFM medium
(Gibco, Carlsbad, CA) at 37°C in a humidified atmo-
sphere of 5% CO2. Regarding the treatment of TGF-β1,
the cells were plated at 5 × 103 per well in 96-well plate,
and cultured in the presence of 10% FBS for 2 days. Then
cells were washed and cultured with serum-free medium
overnight, the next day, cells were treated with TGF-β1 at
different concentrations in serum-free medium, and then
continued to culture for 24 h, 48 h, 72 h, and 96 h, respec-
tively.
Cell growth response
To study the dose/time-effect response of CNE2 to TGF-
β1, cells were plated at 5 × 103 per well in 96-well plate,
and cultured in Keratinocyte-SFM medium for 24 h. Cells
were washed and replaced in growth factors-free medium
overnight and then treated with 0, 2.5, 5, 7.5, 10 and 12.5
ng/mL TGF-β1 in Keratinocyte-SFM medium. The status
of cell growth was determined at 24, 48, 72 and 96 h,
respectively, using Cell Counting Kit-8 (CCK-8) (Dojindo
Laboratories China, Shanghai, China). CCK-8 solution
was added into the plated cells at 10 μl/well, 4 h before
each treatment and then the 96-well plate was swirled for
15 min. The spectrophotometrical absorbance of each
sample was determined at 450 nm.
Analysis of TGF-β receptors and Smads by RT- PCR
Cells were seeded at 1.6 × 105 cells per well into 6-well
plate and cultured in Keratinocyte-SFM medium with
growth factors for 24 h. Cells were washed and replaced
with growth factors-free medium overnight, and then
TGF-β1 was added (final concentration 10 ng/mL) for 3
h. Total RNA was isolated by using an RNA extraction kit
and RNAex reagent (Huashun Biotechnology Co., Ltd.,
Shanghai, China) according to the manufacturer's
instruction. Reverse transcription of 2 ng of total RNA
was performed by using 20 units of AMV reverse tran-
scriptase (BBI); 0.5 ng of oligo (dT) 12-18 primer; 0.5 mM
each of dNTP and 20 units of RNase inhibitor in a total
volume of 20 μL at 42°C for 60 min. The reaction was ter-
minated by heating the mixture at 70°C for 10 min, and
then was chilled on ice. After reverse transcription, PCR
amplification was carried out in a volume of 20 μL con-
taining 1× PCR reaction buffer, 0.2 mM dNTPs, 0.5 μM
of sense and antisense primers (Table 1) and 1 unit Taq
DNA polymerase, The reaction conditions included
denaturation at 95°C for 30 s, annealing at 55°C for 30 s,
and extension at 72°C for 45 s. The cycles were set at 30
cycles for TGF-β type II receptor (TβR-II), Smad2,
Smad3, Smad4, Smad7 and 28 cycles for β-actin. Final
extension was performed at 72°C for 10 min. PCR prod-
ucts were visualized by electrophoresis on a 2% agarose
gel containing ethidium bromide as a fluorescent dye.
Detection of the expression of Smads by Western blotting
Cells were seeded at 1.6 × 105 cells per well into 6-well
plate, and cultured in Keratinocyte-SFM medium with
growth factors for 24 h. Cells were washed and replaced
with growth factor-free medium overnight, and then
TGF-β1 was added (final concentration 10 ng/ml) for 3 h.
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lysis buffer containing 2% SDS, 10% glycerol, and 62.5
mM Tris (pH 7.0). Total proteins were collected by centri-
fuging at 12,000 × g at 4°C for 10 min, and separated by
electrophoresis on a 12% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) gel at 120 V,
transferred to nitrocellulose membrane by blotting. After
washing three times, the membranes were incubated with
rabbit anti-Smad 2/3, rabbit anti-Smad 4, rabbit anti-
Smad 7, rabbit anti-TGF-beta Receptor II, rabbit anti-
Phospho-Smad2 (Ser245/250/255) antibodies (1:1000)
(Cell Signaling Inc, Shanghai, China), and mouse anti-β-
actin (Sigma, Shanghai, China) antibodies, respectively,
for 2 h, then washed and incubated with secondary
horseradish peroxide-conjugated antibody for 1 h. Anti-
gen-antibody complexes were then visualized using an
enhanced chemiluminescence kit (Amersham, Piscat-
away, NJ).
Immunocytochemical analysis of TGF-β type II receptor and 
Smads
Cells were cultured on poly-L-lysine-coated chamber
slides. As the cells confluence reached approximately
40%-50%, the medium was discarded and replaced with a
serum-free Keratinocyte-SFM medium overnight. The
next day, Keratinocyte-SFM medium containing 10 ng/
mL TGF-β1 was added to treat the cells for 3 h, then
washed with PBS for 5 min three times. The cells were
fixed with 4% paraformaldehyde in PBS for 15 min at
room temperature, and then were permeabilized by incu-
bation in 0.1% Triton X-100 for 20 min at 37°C. Endoge-
nous peroxidase was quenched with H2O2 in methanol
(1:50). The cells were blocked with 5% BSA for 20 min at
37°C in a humid chamber. The primary antibodies were
applied at a 1:100 dilution at 4°C overnight, the primary
antibodies included anti-TβR II, anti-Smad2, anti-Smad3,
anti-Smad4, and anti-Smad7 (Santa Cruz Biotechnology,
Inc. Santa Cruz, CA). The biotinylated secondary anti-
body was applied for 20 min at room temperature in a
humid chamber, and then the slides were rinsed in PBS
for 5 min. Streptavidin biotin complex (SABC) was added
to the slides and incubated in a humid chamber for 30
min at room temperature, and then rinsed in PBS for 5
min. The slides were applied with an aliquot of 3, 3'-
Diaminobenzidine (DAB) to develop brown color. Coun-
ter-staining was performed with modified Mayer's hema-
toxylin for 10 s, washed with water for 10 min and
mounted with resinous mounting medium after dehydra-
tion.
Results
CNE2 cells are insensitive to growth suppression by TGF-β1
TGF-β1 is a potent growth inhibitor of epithelial cells. To
test the response of human NPC cells to TGF-β1, we
examined the growth pattern of CNE2 cells after TGF-β1
treatment. The rate of cell growth and the metabolic
activity was indicated the degree of the growth suppres-
sion by TGF-β1 and a time course study regarding the
growth suppression of CNE2 was performed. The data
showed that the effect of growth suppression by TGF-β1
against CNE2 was not observed. Instead of suppression,
CNE2 continued to grow after 24 h with TGF-β1 treat-
ment at the various concentrations (2.5, 5, 7.5, 10, and
12.5 ng/ml), and reached a growth peak at 48 h after
TGF-β1 treatment. Although TGF-β1 caused a slight
increase in proliferation on CNE2 after TGF-β1 treat-
ment by 48 h, no statistical significance was found com-
pared to the untreated controls (Figure 1A). The
insensitivity to TGF-β1 implied that the TGF-β1 signaling
Table 1: PCR primer used in the experiment
Target mRNA Primer sequence5'-3' Product Size (bp) GenBank
Accession No
TβRII Sense gca cgt tca gaa gtc ggt ta 493 D50683
Antisense gcg gta gca gta gaa gat ga
Smad2 Sense aag aag tca gct ggt ggg t 246 AF027964
Antisense gcc tgt tgt atc cca ctg a
Smad3 Sense cag aac gtc aac acc aagt 308 NM005902
Antisense atg gaa tgg ctg tag tcg t
Smad4 Sense cca gga tca gta ggt gga at 243 U44378
Antisense gtc taa agg ttg tgg gtc tg
Smad7 Sense gcc ctc tct gga tat ctt ct 320 AF015261
Antisense gct gca taa act cgt ggt ca
β-actin Sense aca atg tgg ccg agg ctt t 260 M10277
Antisense gca cga agg ctc atc att ca
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the effect of growth suppression on the normal nasopha-
ryngeal epithelial cells by TGF-β1, we performed the Cell
Counting Kit-8 assay on the NP69 cells exposed to TGF-
β1. Under the same experimental conditions, we used
TGF-β1 at a concentration of 10 ng/ml because this con-
centration induced a high proliferation rate in the CNE2
cells among all time points tested. We monitored cell
growth within 96 h after TGF-β1 treatment, and found
that TGF-β1 did have the effect of growth suppression on
NP69 cells. Adding TGF-β1 at a concentration of 10 ng/
ml to the cell culture medium significantly reduced the
viable cell number after 48 h, and the suppression rate of
NP69 cells by TGF-β1 was statistically significant com-
pared to the untreated NP69 cells (Figure 1B).
TGF-β type II receptor and Smads in CNE2 cells
To investigate alterations of the TGF-β/Smad signaling
pathway in CNE2 cells, the TGF-β type II receptor (TβR-
II) and the TGF-β/Smad signaling components-Smads
signal transduction were explored at both mRNA level
and protein level by real time RT-PCR, using specific
primers according to GenBank database sequences, west-
ern blotting and immunocytochemical analysis, respec-
tively. First, we investigated TβR-II mRNA expression
which is an upstream signaling partner of the TGF-β/
Smad signaling pathway, while the normal nasopharyn-
geal epithelial cells were used as control. Under the same
culture conditions, we found that TβR-II was significantly
up-regulated in CNE2 cells compared to the levels
observed in NP69 cells. We further evaluated the Smads
which are the principal intracellular components of the
TGF-β signaling pathway, and the results showed that
Smad2, Smad3 and Smad4 mRNA all increased signifi-
cantly in CNE2 cells compared to the levels observed in
NP69 cells. However, the mRNA level of smad7, known
as an inhibitory Smad, remained at same level as that
observed for the normal nasopharyngeal cells (Figure 2A,
2B). To investigate the protein expression of the TβR-II
receptor and Smads, western blotting was performed in
NP69 and CNE2 cells. We found that Smad2, Smad3,
Smad4 and TβR-II were also up-regulated in protein lev-
els, but Smad7 protein level were no different compared
to that observed in NP69 cells (Figure 3). To further local-
ize the expression of the above signaling components in
CNE2 cells, immunocytochemical staining was con-
ducted. A positive staining of TβR-II was found in most
CNE2 cells, and the cell membrane was the main localiza-
tion of the protein. The positive staining of Smad2,
Smad3 and Smad4 was found in regions of both the cyto-
plasm and nucleus, while the staining of Smad7 was
mainly in the nucleus (Figure 4A).
TGF-β1 inducing activation and translocation of Smad 
proteins in NPC cells
To determine whether Smad is activated and translocated
in response to TGF-β1 stimulation in CNE2 cells, we
Figure 1 Loss of the Growth-Inhibitory Effect of TGF-β1 on CNE2 
cells. CNE2 and/or NP69 cells were seeded in 96-well plate at 5 × 103 
cells/well. (A) 2.5-12.5 ng/ml or (B) only 10 ng/mlTGFβ1 was added af-
ter 24, 48, 72, and 96 hours. Cell counting assay was used to indicate 
the degree of cell growth. Results were presented as the spectropho-
tometrical absorbance of cells treated with CCK-8 solution at the wave-
length of 450 nm. * Statistically significant (P < 0.05, t-test) as compared 




Figure 2 The mRNA level of the TGF-β receptor II and the Smads 
in CNE2 and NP69 cells. (A) Expression level of the TβRII, Smad 2, 
Smad 3, Smad 4, Smad 7 in CNE2 cells and NP69 cells by RT-PCR using 
specific primers. β-actin was used as a control and was further to nor-
malize. (B) Bar diagram of the TβRII, Smad 2, Smad 3, Smad 4, Smad 7 
mRNA level from densitometric measurement of three real-time quan-
titative PCR from three separate treatments. * Statistically significant (P 
< 0.05, t-test) as compared with NP69 group.** Statistically significant 
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lated (activated) Smad2/3 by immunocytochemistry
staining. No phosphorylated Smad2/3 staining was
exhibited in CNE2 cells without TGF-β1 stimulation,
however, a very strong staining of phosphorylated
Smad2/3 was found in regions of both the cytoplasm and
nucleus of the CNE2 cells after TGF-β1 treatment com-
pared to untreated cells. This result indicated that Smad2
was phosphorylated and activated after TGF-β1 stimula-
tion. Furthermore, we investigated the inhibitory Smad-
Smad 7 protein in response to TGF-β1 stimulation in
CNE2 cells. The results indicated that the positive stain-
ing of Smad 7 initially was localized in the region of the
nucleus before TGF-β1 treatment. However, positive
staining of Smad 7 was observed in the cytoplasm after
TGF-β1 treatment, which implied that Smad 7 translo-
cated from the nucleus to the cytoplasm in response to
the TGF-β1 stimulation (Figure 4B).
Discussion
TGF-β1 is a very potent inhibitor of many epithelial
tumors, however, the role of TGF-β1 in nasopharyngeal
Carcinoma progression is ambiguous. In the present
study herein, we demonstrated for the first time that
CNE2 cells have lost the sensitivity to growth suppression
by TGF-β1 (Figure 1). Interestingly, rather than a defec-
tive TGF-β/Smad signaling pathway which leads to a loss
of response to the growth suppression effect of TGF-β1,
our results indicate that the TGF-β/Smad signaling is
functional in the CNE2 cell after treatment TGF-β1. The
TβR-II is expressed normally, while Smads 2, Smads 3,
Smads 4 are significantly increased at the mRNA level
and the protein level compared to the levels observed in
the normal nasopharyngeal epithelial cells (Figure 2, 3).
The mRNA and protein expression of Smad7 remains
unchanged in the CNE2 cells. Immunocytochemistry
demonstrated that the transmembrane receptor TβR-II
and the intracellular component Smads are also detect-
able (Figure 4A), where pretreatment of CNE2 cells with
TGF-β1 causes activation of the Smad 2 protein, and the
inhibitory Smad 7 translocates from the nucleus into the
cytoplasm (Figure 4B).
It has been demonstrated that TGF-β1 binds to the
TβR-II and then phosphorylated the Smad2 and Smad3
after stimulation by TGF-β, and subsequent form hetero-
oligomers with the common mediator Smad4. The
formed Smad complex then translocates into the nucleus
Figure 3 The expression of the TGF-β receptor II and the Smads in 
CNE2 and NP69 cells. Expression level of the TβRII, Smad 2, Smad 3, 
Smad 4, Smad 7 in CNE2 cells and NP69 cells by western blot. Actin was 
used as a protein loading control and was further to normalize. Relative 
density was account between NP69 and CNE2 group.
TGF-
Figure 4 Localization of expression of the TβR-II, Smad2, Smad3, 
Smad4, Smad7 and phosphorylated Smad2 in CNE2 cells. (A) The 
TβR-II was located mainly in the cell membrane, and positive staining 
Smad2, Smad3, Smad4, was found in regions of both cytoplasm and 
nucleus, while the staining of Smad7 was mainly in the area of nucleus. 
(B) Phosphorylated Smad2 was undetectable in CNE2 cells without 
TGF-β1, after stimulation with TGF-β1, phosphorylated Smad2 could 
be detected in the cytoplasm of CNE2 cells, while Smad7 located orig-
inally in nuclear without TGF-β1, and it could be detected in the cyto-
plasm after stimulation of TGF-β1.
A
B
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Studies have demonstrated that loss of the TGF-β/Smad
signaling function including defects in TGF-β receptors
and/or downstream signal molecular Smad proteins is
associated with tumor progression, and specific defects in
this signalling pathway has been found in many cancers,
including pancreatic, breast, ovarian, colorectal, liver,
prostate cancer, leukemia, etc. [24-30]. Disruption of this
TGF-β/Smad signaling cascade is considered an impor-
tant mechanism by which tumor cells can escape growth
suppression, and many cancer cells lose responsiveness to
TGF-β-induced growth inhibition [10]. Our results indi-
cate that CNE2 cells are not sensitive to the effect of
growth suppression by TGF-β1 (Figure 1), suggesting that
CNE2 cells may eliminate a critical negative control of
TGF-β1 signaling. To assess whether the TGF-β/Smad
signaling pathway in CNE2 cells changed or not, we
investigated the expression of the components in the
TGF-β/Smad signaling pathway, including TβR-II,
Smad2, Smad3, Smad4, and Smad7. The results showed
that all of these components of the TGF-β/Smad signal-
ing pathway were expressed, and the mRNA expression of
Smad2, Smad3 and Smad4 markedly increased (Figure 3).
However the mRNA expression of the transmembrane
receptor-TβR-II and Smad7 which participates in nega-
tive control of TGF-β1/Smad signaling pathway were left
unchanged compared with normal nasopharyngeal epi-
thelial cells (Figure 2). We further tested whether TGF-β1
can cause activation of Smad2 because phosphorylated
activation of Smad2 is a key step in TGF-β1/Smad signal-
ing for the induction expression of downstream mole-
cules, and the results showed that exposure of cells to
TGF-β1 did induced the phosphorylation of smad2 in
CNE2 cells (Figure 4B), and TGF-β1 can also induce the
translocation of smad7 from nucleus to cytoplasm (Fig-
ure 4B), suggesting that the TGF-β1/Smad signaling
transduction is functional.
Although our results are different from the reports that
the TGF-β/Smad signaling pathway is defective in the
cancer cells, it is possible that the TGF-β/Smad signaling
transduction is functional but the growth of CNE2 cells
themselves are not suppressed by TGF-β1. The reason
could be as follows. First, hundreds of genes are activated
or repressed in response to TGF-β1 ligand stimulation,
and the particular array of genes is cell-type- and condi-
tion-specific because the transcription factors utilized are
cell-type- and condition-specific [31,32]. TGF-β1 has
widely varying and divergent cellular effects although it
uses an identical signaling system. Hence, it could be that
CNE2 cells achieve resistance to the tumor-suppressor
effect of TGF-β1, but remain responsive to the tumor-
promoter effects of TGF-β1 via selective alterations of
this signaling pathway. Second, TGF-β1 has a broad and
multifunctional role because of this intricate system of
components. Besides Smad-mediated transcription,
TGF-β1 could also activate other signaling cascades,
including MAPK, Erk, JNK and other yet-to-be-deter-
mined Smad-independent pathways [33]. Although this
convergence of Smad-dependent and Smad-independent
pathways in TGF-β family signaling can result in cooper-
ativity, these pathways may also counteract each other,
thereby enabling CNE2 cells to escape the tumor-sup-
pressor effects of TGF-β1 and becoming resistant to
TGF-β1-induced growth inhibition. Third, although it is
generally accepted that TGF-β1 acts as a tumor suppres-
sor through its ability to induce growth arrest at early
stages, TGF-β1 can also act as a tumor promoter. Numer-
ous studies have demonstrated that most cancer cells
secrete larger amounts of TGF-β1 than their normal cell
counterparts, and this overexpression is strongest in the
most advanced stages of malignancies including nasopha-
ryngeal carcinoma [6,7]. These malignancies can subvert
TGF-β1 for their own purposes of survival, promoting
angiogenesis, cell spreading, immunosuppression, tumor
cell invasion and metastasis at late stages of tumorigene-
sis [34-37]. The CNE2 cell is a late-phage differentiation
NPC cell line, so TGF-β1 is likely to serve as a tumor pro-
moter rather than a tumor suppressor in CNE2 cells.
Lastly, although the mechanism by which TGF-β1
switches its growth inhibitory effect into growth stimula-
tory effect is not well understood, TGF-β1 has been
shown to increase the production of several mitogenic
growth factors including TGF-α, FGF and EGF [38].
In addition, prolonged experimental exposure to high
levels of TGF-β has been demonstrated to promote neo-
plastic transformation of intestinal epithelial cells, and
TGF-β1 stimulates the proliferation and invasion of
poorly differentiated and metastatic colon cancer cells
[39,40]. Currently, less is known regarding the role of
TGF-β1 and the TGF-β/Smad signaling pathway in the
CNE2 cell, however, one study by using DNA microarray
analysis demonstrates that the genes of TβR-I and TβR-II
are upregulated in CNE2 cells [41], which is consistent
with the our observation that TβR-II is expressed nor-
mally in CNE2 cells (Figure 2, 3).
In summary, an important issue addressed in this study
is that CNE2 cells are not sensitive to growth suppression
by TGF-β, but the TGF-β/Smad signaling transduction is
functional. Further work is necessary to delineate a more
detailed spectrum of the TGF-β/Smad signaling pathway,
as well as understanding its crosstalk with other signaling
pathways in CNE2 cells. By analogy to the situation in
nasopharyngeal carcinoma, the components of the TGF-
β/Smad signaling pathway may be a new target in the
chemoprevention and chemotherapy of nasopharyngeal
carcinoma.
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